drugset
drugset / Trial / NCT05501717

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

NCT05501717 ↗

Phase 1 Active not recruiting 48 enrolled Alexion Pharmaceuticals, Inc.
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of ALXN2030 in healthy participants.

Timeline

Start
2022-08-16
Primary completion
2025-10-09
Completion
2026-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject ALXN2030 Unknown — Subcutaneous

Indications

No indication recorded.